-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells.

-  In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73^High and PD-L1 TPS≥1% responded to the combination...